ClinicalTrials.gg
CompletedNCT06703346Updated Aug 13, 2026

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

A Phase 2 interventional study of Letetresgene autoleucel (Lete-Cel (GSK3377794)) and Cyclophosphamide in Neoplasms, sponsored by USWM CT, LLC. Completed at 38 sites in 7 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by USWM CT, LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.
  • Registered 4 years 10 months after the study started (first participant enrolled Dec 2019, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Study summary

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Adoptive T-cell therapy
  • Letetresgene autoleucel
  • Lete-cel
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 82 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

USWM CT, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥10 years of age at the time of signing the .
  • Participant scheduled to receive clinical drug product supply must also weigh ≥40 kg.
  • Participant has a diagnosis of synovial sarcoma or myxoid/round cell liposarcoma, confirmed by local histopathology with evidence of disease-specific translocation.
  • Participant has advanced ( or unresectable) synovial sarcoma or myxoid/round cell liposarcoma. Unresectable refers to a tumor lesion in which clear surgical excision margins cannot be obtained without leading to significant functional compromise.
  • Male or female. requirements will apply at the time of leukapharesis and treatment.
  • ≥24 weeks
  • Participant has confirmed evidence of a relevant disease-specific translocation per below:
  • For synovial sarcoma, presence of a translocation involving chromosome 18 (SYT gene) and/or chromosome X (SSX1, SSX2 or SSX4 genes).
  • For myxoid/round cell liposarcoma, presence of a translocation involving chromosome 12 (DDIT3 gene) and/or chromosome 16 (FUS gene) and/or chromosome 22 (EWSR1 gene).
  • Participant is either currently being treated with or has completed at least one standard-of-care treatment including anthracycline-containing regimens (e.g., doxorubicin alone, doxorubicin with ifosfamide) for advanced (metastatic or inoperable) disease. Participants who are intolerant to anthracycline may receive ifosfamide alone unless intolerant to or ineligible to receive ifosfamide. Participants who received anthracycline-based therapy in the /adjuvant setting and progressed will be eligible.
  • Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles by a validated test in a designated central lab prior to leukapheresis
  • Participant's tumor has been pathologically reviewed by a designated central laboratory with confirmed positive NY-ESO-1 expression defined as ≥30% of cells that are 2+ or 3+ by immunohistochemistry.
  • ≥45% with no evidence of pericardial effusion.
  • Performance status: for participants \<16 years of age, Lansky >60, or for participants ≥16 and \<18 years of age, >60, or for participants ≥18 years of age, (ECOG) of 0-1.
  • Participant must have adequate organ function and blood cell counts, within 7 days prior to the day of the leukapheresis procedure
  • Participant is fit for leukapheresis and has adequate venous access for the cell collection
  • Female participants of (FCBP) must have a negative urine or serum pregnancy test.
  • Participant has according to v1.1.
  • Participant has documented radiographic evidence of disease progression from .
  • A (excisional, incisional, or core) of non-target tumor tissue obtained within 28 days prior to initiating lymphodepleting chemotherapy is mandatory if clinically feasible. This biopsy will be used as baseline for biomarker analyses. If it is not feasible to obtain a fresh biopsy, an archival tumor tissue (FFPE block) taken preferably after completion of the participant's last line of therapy, preferably within 90 days prior to initiating lymphodepleting chemotherapy, may be accepted.
  • A haematologist has been consulted prior to lymphodepletion in participants who have had a serious/significant bleeding/thrombosis history.

Exclusion criteria

Exclusion Criteria:

  • Central nervous system (CNS) .
  • Any other prior that is not in complete remission.
  • Previous treatment with genetically engineered NY-ESO-1-specific T cells.
  • Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
  • Prior gene therapy using an integrating vector
  • Previous hematopoietic stem cell transplant
  • systemic illness (serious active infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that in the judgment of the Investigator would compromise the participant's ability to tolerate protocol therapy or significantly increase the risk of complications) or prior or active demyelinating disease
  • Participant has received cytotoxic therapy within 3 weeks prior to lymphodepleting chemotherapy
  • Systemic or any other therapy within 2 weeks prior to lymphodepleting chemotherapy.
  • Participant has received ≥50 Gy to a significant volume of the pelvis, long bones or spine, or a cumulative dose of radiation that, in the Investigator's opinion would predispose patients to prolonged cytopenia after lymphodepletion.
  • All of the participant's have been irradiated within 3 months prior to lymphodepletion. An irradiated measurable lesion with unequivocal progression following irradiation may be considered a target lesion regardless of time from last radiotherapy dose.
  • Participant has received an anti-cancer vaccine within 2 months in the absence of tumor response. The participant should be excluded if their disease is responding to an experimental vaccine given within 6 months.
  • Participant has received within 4 weeks prior to lymphodepletion or intends to receive live vaccine during the 3-month period following administration of lete-cel.
  • Participant has received immune therapy (monoclonal antibody therapy, ) within 4 weeks of lymphodepletion.
  • Participant had major surgery ≥28 days of first dose of study intervention
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Letetresgene autoleucel

    Drug: Letetresgene autoleucel (Lete-Cel (GSK3377794)) · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

06

What researchers measure

Primary outcomes

  1. ORR (Overall Response Rate)

    ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 relative to the total number of participants in the analysis population. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline). 95% CI is based on Clopper-Pearson exact confidence interval.

    Time frame: Up to approximately 36 months

Secondary outcomes

  1. DCR (Disease Control Rate)

    DCR, is defined as the percentage of participants with a confirmed CR, PR, or SD with minimal 12 weeks duration relative to the total number of participants within the analysis population at the time of primary analysis as determined by independent central review per RECIST v1.1. The observed DCR will be reported along with 95% Clopper-Pearson exact confidence interval (CI). DCR will be analyzed based on PEAP and mITT populations.

    Time frame: Up to approximately 36 months

  2. PFS (Progression Free Survival)

    PFS, is defined as the time from the date of T-cell infusion until the earliest date of radiological PD as assessed by independent central review per RECIST v1.1, or death due to any cause. For the analysis of PFS, if the participant received subsequent anticancer therapy prior to the date of documented events, PFS will be censored at the last adequate disease assessment (e.g., assessment when visit level response was CR, PR, or SD) prior to the initiation of the new anticancer therapy. If a participant does not have an adequate post-baseline disease assessment that is no later than the date of initiation of anti-cancer therapy, PFS will be censored at the date of the T-cell infusion date.

    Time frame: Up to approximately 54 months

  3. OS (Overall survival)

    OS is defined as the interval of time between the date of T-cell infusion and the date of death due to any cause. For participants who do not die, time of death will be censored at the date of last contact. The date of death should be taken from that recorded on the Record of Death page. Death on study due to any cause will be included. Survival will be listed and summarized using Kaplan-Meier quartile estimates along with 2-sided 95% CI.

    Time frame: up to 15 years post-T-cell infusion

  4. DOR (Duration of response)

    DOR is defined as, in the subset of participants who show a confirmed CR or PR as assessed by independent central review per RECIST v1.1, the time from first documented evidence of CR or PR until the first documented sign of disease progression or death. Duration of response will be summarized descriptively, if data warrant, using Kaplan-Meier medians and quartiles. Censoring: same as PFS censorship table.

    Time frame: Up to approximately 54 months

  5. TTR (Time to response)

    TTR is defined as the time from the date of T-cell infusion to initial date of confirmed response (PR or CR) as assessed by independent central review per RECIST v1.1 in the subset of participants who achieved a confirmed PR or CR. TTR will be listed and summarized descriptively using median and quartiles in the subset of participants with a confirmed response of PR or CR. Efficacy listings such as BOR, DOR, PFS and OS will be reported for the PEAP and mITT populations.

    Time frame: Up to approximately 54 months

  6. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.

    Time frame: Up to approximately 54 months

  7. Number of Participants with AEs of Special Interest (AESIs)

    An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. AESIs included cytokine release syndrome (CRS), hematopoietic cytopenias (including pancytopenia and aplastic anemia), graft vs host disease (GVHD), ICANS, Guillain-Barre syndrome, treatment-related inflammatory response at tumor site(s), and neutropenia Grade 4 lasting ≥28 days.

    Time frame: Up to approximately 54 months

  8. Number of Participants with TEAEs and TESAEs by Severity

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. AEs and SAEs were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences; Grade 5- Death related to AE.

    Time frame: Up to approximately 54 months

  9. Number of Participants with AESIs by Severity

    An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. AESIs included cytokine release syndrome (CRS), hematopoietic cytopenias (including pancytopenia and aplastic anemia), graft vs host disease (GVHD), ICANS, Guillain-Barre syndrome, treatment-related inflammatory response at tumor site(s), and neutropenia Grade 4 lasting ≥28 days.

    Time frame: Up to approximately 54 months

  10. Percentage of Participants with Replication Competent Lentivirus (RCL) Positive

    RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).

    Time frame: Up to approximately 54 months

  11. Instances of Insertional Oncogenesis (IO)

    Instances of Insertional Oncogenesis (IO) was summarized descriptively

    Time frame: Up to approximately 54 months

  12. Maximum Transgene Expansion (Cmax)

    Cmax was defined as maximum observed persistence, determined directly from the persistence-time data. Blood samples were collected for PK analysis

    Time frame: Day 1 to Day 14

  13. Time to Cmax (Tmax)

    Tmax was defined as time to reach Cmax, determined directly from the persistence-time data. Blood samples were collected for PK analysis.

    Time frame: Day 1 to Day 14

  14. Area Under the Time Curve from Zero to Time 28 Days (AUC [0-28])

    Area under the persistence-time curve from time zero to Day 28. Blood samples were collected for PK analysis.

    Time frame: Up to 28 days

07

Study locations

38 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Hospital and Clinics
    Stanford, California 94305, United States
  • Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Iowa College of Medicine
    Iowa City, Iowa 52242-1009, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering cancer center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University-Columbus
    Columbus, Ohio 43210, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh, Hillman Cancer centre
    Pittsburgh, Pennsylvania 15232, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • University Of Texas Southwestern Medical Center
    Dallas, Texas 75390-8565, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9063, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109-1024, United States
  • Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de L'Est-De-Lile-De-Montreal
    Montreal, Quebec H1T 2M4, Canada
  • Centre Léon Bérard
    Lyon, 69373, France
  • CHU de Bordeaux GH Sud Hôpital Haut Lévêque
    Pessac, 33604, France
  • Fondazione IRCCS Instituto Nazionale Dei Tumori
    Milan, Lombardy 20133, Italy
  • Ircss Istituto Clinico Humanitas
    Rozzano (MI), Lombardy 20089, Italy
  • The Netherlands Cancer Institute
    Amsterdam, 1066 CX, Netherlands
  • Hospital Santa Creu Y Sant Pau
    Barcelona, 08025, Spain
  • Ico Duran y Reynals l'Hospitalet de Llobrega
    Barcelona, 08907, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Virgen Del Rocio
    Seville, 41013, Spain
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • University College Hospital-London
    London, WC1E 6AG, United Kingdom
  • Christie Hospital NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Mar 2024, 50 months.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 50 months is above that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 25, 2024
StartActual
Dec 31, 2019
Primary completionActual
Mar 1, 2024
CompletionActual
Jul 24, 2026
Results delay requested
Jul 10, 2025
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703346
Lead sponsor
USWM CT, LLC
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Dec 31, 2019
Primary completion
Mar 1, 2024
Completion
Jul 24, 2026
Last update
Aug 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letetresgene autoleucel

Start the discussion